{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:13:01Z","timestamp":1780956781839,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Considering the general view that unconventional immune effectors play a major role in antitumor immunity, we recently postulated that the distinct new innate CD8 T-cell pool (co-expressing the transcription factor Eomesodermin and innate markers such as KIR\/NKG2A) may counteract tumor cells, and thereby be potential target for cancer therapy. Here, to test this assumption, we used successfully targeted anti-leukemic therapy discontinuation (TFR) in chronic myeloid leukemia (CML). Numerical and functional status of innate CD8 T-cells, iNKT cells and \u03b3\u03b4 T-cells, in comparison with NK cells, was compared longitudinally between non-relapsed patients (i.e., with &amp;gt; 12 months TFR) and relapsed patients (i.e., who experienced molecular recurrence during the first 12 months after TKI cessation) in a prospective pilot cohort (n=32), starting from treatment discontinuation (D0). Perforin, a key cytotoxic immune player, was expressed in a significantly higher proportion of both innate CD8 T-cell and NK-cell subsets in non-relapsed patients, compared with relapsed patients at D0. In parallel, we assessed the expression of PD-1, an exhaustion marker used as target in cancer therapy. For all T-cell subsets, surface-expression level of PD-1 decreased in non-relapsed patients compared with relapsed patients at D0. This was particularly the case when considering iNKT cells for which surface-expression level of PD-1 even decreased relative to healthy control subjects. Lastly, we found a negative correlation between the proportion of innate CD8 T-cells expressing PD-1 and those expressing perforin in non-relapsed patients at D0. The fact that this was not the case in conventional CD8 T-cells is compatible with a reprogrammed effector profile preferentially targeting innate CD8 T-cells in non-relapsed patients. All in all, our results highlight NK cells and innate CD8 T-cells harboring cytotoxic content, as well as global downregulation of PD-1-expression on effector T-cells, as potential predictive functional signatures for successful TFR in CML. Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1473139","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:13:31Z","timestamp":1731651211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Amandine","family":"Decroos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meddour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Demoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Piccirilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ragot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Gombert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Barbarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cayssials","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41467-019-08604-4","article-title":"Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions","volume":"10","author":"Gutierrez-Arcelus","year":"2019","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal anti-tumor immunotherapeutic","volume":"4","author":"Fujii","year":"2013","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.03.018","article-title":"CD1d-restricted iNKT cells, the \u201cSwiss-Army knife\u201d of the immune system","volume":"20","author":"Matsuda","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619954","article-title":"The dual roles of human \u03b3\u03b4 T cells: anti-tumor or tumor-promoting","volume":"11","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0513","article-title":"[amp]]gamma;\u03b4 T-cell receptors derived from breast cancer\u2013infiltrating T lymphocytes mediate antitumor reactivity","volume":"8","author":"Janssen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22130-1","article-title":"Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma","volume":"8","author":"Gherardin","year":"2018","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160943","article-title":"Mucosal-associated invariant T cells in hematological Malignancies: Current knowledge, pending questions","volume":"14","author":"Treiner","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545539","article-title":"Evidence for eomesodermin-expressing innate-like CD8(+) KIR\/NKG2A(+) T cells in human adults and cord blood samples","volume":"45","author":"Jacomet","year":"2015","journal-title":"Eur J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031051","article-title":"Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen","volume":"198","author":"Berg","year":"2003","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00316","article-title":"Phenotype of NK-like CD8(+) T cells with innate features in humans and their relevance in cancer diseases","volume":"8","author":"Barbarin","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674016","article-title":"Allotransplantation is associated with exacerbation of CD8 T-cell senescence: the particular place of the innate CD8 T-cell component","volume":"12","author":"Daniel","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00688","article-title":"The hypothesis of the human iNKT\/innate CD8(+) T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia","volume":"7","author":"Jacomet","year":"2017","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br J Haematology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2018.02.014","article-title":"Enhanced perforin expression associated with dasatinib therapy in natural killer cells","volume":"68","author":"Iriyama","year":"2018","journal-title":"Leukemia Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1038\/s41598-020-60195-z","article-title":"Innate T-\u03b1\u03b2 lymphocytes as new immunological components of anti-tumoral \u201coff-target\u201d effects of the tyrosine kinase inhibitor dasatinib","volume":"10","author":"Barbarin","year":"2020","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02048","article-title":"Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: A pan-cancer study","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0925","article-title":"Activating mucosal-associated invariant T cells induces a broad antitumor response","volume":"9","author":"Ruf","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.2.401.401","article-title":"Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia","volume":"76","author":"Verfaillie","year":"1990","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709058306","article-title":"The role of autologous natural killer cells in chronic myelogenous leukemia","volume":"27","author":"Pierson","year":"1997","journal-title":"Leukemia Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142043","article-title":"Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients","volume":"42","author":"Rossignol","year":"2012","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15858","article-title":"Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br J Haematology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010042","article-title":"Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission","volume":"10","author":"Vig\u00f3n","year":"2020","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to Malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01492","article-title":"V\u03b39V\u03b42 T cells in the bone marrow of myeloma patients: A paradigm of microenvironment-induced immune suppression","volume":"9","author":"Castella","year":"2018","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03737-y","article-title":"Transcriptional and epigenetic regulation of PD-1 expression","volume":"78","author":"Chi","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0106OC","article-title":"Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis","volume":"190","author":"Jiang","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10082","DOI":"10.1038\/s41598-023-36468-8","article-title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","volume":"13","author":"Balasko","year":"2023","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282710","article-title":"Anti-PD1 does not improve pyroptosis induced by \u03b3\u03b4 T cells but promotes tumor regression in a pleural mesothelioma mouse model","volume":"14","author":"Lui","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1473139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:13:36Z","timestamp":1731651216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1473139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2024.1473139"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1473139","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"article-number":"1473139"}}